Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott (ABT) reported one-year VERITAS study results showing complete left atrial appendage closure in 96.3% of patients evaluated by heart ultrasound.
The study evaluates the investigational Amulet 360 device for people with atrial fibrillation, an irregular heartbeat, not caused by a heart valve issue. Complete closure meant zero mm leak. Through one year, more than 98% of patients remained free from ischemic stroke or systemic embolism, a blood-clot complication. More than 99% were free from fluid buildup around the heart requiring intervention, and more than 98% were free from cardiovascular-related mortality. Major bleeding events were not reported in 93.4% during the first year.
VERITAS includes more than 450 patients, including roll-in patients, at over 30 hospitals. Amulet 360 received CE Mark approval in August 2026; its U.S. use remains investigational only.
Abbott (NYSE: ABT) reported that its investigational SonicForce coronary calcium-treatment system met both primary endpoints in the TECTONIC clinical trial.
The study enrolled 335 patients at 40 U.S. sites with severely calcified coronary artery disease. The primary safety endpoint showed a 0.3% 30-day target lesion failure rate, while the primary effectiveness endpoint showed 97% procedural success. Secondary endpoints were also met: remaining vessel blockage after treatment and stent delivery was less than 50% in all patients assessed by the core laboratory. Major adverse cardiovascular events occurred in 0.3% of the as-treated population.
SonicForce uses acoustic pressure waves to crack calcium before stent placement. It has not received FDA approval and remains limited to investigational use. Results were presented at TCT and published in JACC: Cardiovascular Interventions.
Abbott (NYSE: ABT) has initiated the CROWN-MV pivotal trial to evaluate its investigational Cephea mitral valve replacement system. The study assesses safety and effectiveness in people with symptomatic mitral valve disease who are not candidates for surgery or transcatheter repair. It will enroll up to 585 people in the U.S., Canada and Europe with moderate-to-severe or severe mitral regurgitation, or valve dysfunction associated with calcium buildup at the valve base.
The first enrollment occurred at Ascension Via Christi Hospital in Wichita, Kansas. Researchers will present 30-day early feasibility outcomes for Cephea's third-generation delivery system at TCT on November 1, 2026. Abbott also outlined presentations on other cardiovascular devices, including results from the PARADIGM trial that supported recent FDA approval of the Amplatzer Paraclose PVL Occluder.
Abbott (NYSE: ABT) launched its next-generation Oncodetect test to detect traces of cancer in blood during and after treatment. The personalized test uses tumor tissue and whole-genome sequencing to identify DNA signals for subsequent blood testing. It tracks up to 5,000 patient-specific variants, versus up to 200 previously, with a detection limit below one part per million under high-end inputs.
In locally advanced esophageal cancer, repeated testing detected tumor DNA before recurrence in all 14 patients who experienced recurrence. In the PARTNER triple-negative breast cancer study, one post-surgery blood draw identified 90% of patients who later experienced distant recurrence within five years. Beta-CORRECT showed a 30% absolute improvement in sensitivity for recurrence within two years versus the first-generation test in stage II–IV colorectal cancer. More than 20 studies are ongoing.
Abbott (ABT) presented Beta-CORRECT study results showing improved colorectal cancer recurrence detection with its whole-genome sequencing Oncodetect blood test.
The study analyzed post-surgical samples from 279 patients, predominantly with stage II and III disease. A single blood draw approximately one month after surgery achieved 72.2% sensitivity for recurrence within two years, versus 42.2% with the whole-exome sequencing test—a 30-percent absolute improvement. Sensitivity measures how often a test identifies patients who experience recurrence. Patients with detectable circulating tumor DNA, or tumor DNA in blood, had a 10.6-fold higher recurrence risk than those without detectable tumor DNA. Two-year disease-free survival was 36.2% versus 92.3%, respectively.
Abbott (ABT) reported third-quarter sales of $13,013 million and reaffirmed the midpoint of its full-year adjusted earnings guidance. Sales rose 14.5 percent year over year, or 7.0 percent on a comparable basis. GAAP diluted earnings per share were $0.53; adjusted diluted EPS, excluding specified items, was $1.42. Abbott tightened its full-year adjusted EPS range to $5.50 to $5.55 and projects approximately 6.0 percent comparable sales growth.
Third-quarter comparable sales increased across all four segments, led by Established Pharmaceuticals at 8.4 percent and Medical Devices at 7.8 percent. First-nine-month Nutrition sales declined 1.3 percent on a reported basis. Portfolio additions included FDA approvals for Libre Duo and TactiFlex Duo, CE Mark for Amulet 360, and the launch of FDA-approved SimpleScreen CRC, a blood-based colorectal cancer screening test.
Abbott (ABT) plans to separate its global Nutrition business into an independent, publicly traded company by the end of 2027. The business has approximately $8.5 billion in annual sales and includes Similac, PediaSure, Pedialyte, Glucerna and Ensure.
Abbott intends to distribute the new company's shares to its shareholders in a transaction intended to be tax-free for U.S. federal income tax purposes. Shareholders would own both companies. Abbott expects their combined dividend to equal its dividend at separation and projects approximately $42 billion in sales for the remaining Abbott business.
Completion requires regulatory approvals, an effective Form 10 registration statement and final board approval. Abbott expects one-time transaction charges before separation. The planned separation will not affect its 2026 guidance or the 2027 guidance it plans to provide in January.
Abbott (NYSE: ABT) launched Ensure Max Protein 3-in-1 Muscle Support, a powder combining protein, creatine and calcium HMB in one product.
A serving contains 30 grams of protein, 5 grams of creatine monohydrate and 3 grams of calcium HMB. Abbott describes the formula as supporting muscle building, exercise recovery and muscle preservation. The product is available in chocolate and vanilla at Walmart and Amazon in a 28-ounce format. The suggested serving is two scoops mixed with 12 fluid ounces of liquid once daily. It is third-party NSF Contents Certified.
Abbott (NYSE: ABT) received FDA approval for CardioMEMS HF System updates that enable patient access to heart-pressure readings through a smartphone app.
Care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure, the pressure of blood flowing from the heart to the lungs, through the CardioGuide HF App. This pressure can rise weeks before patients experience symptoms of worsening heart failure. The system measures it using an implanted sensor.
The approved capabilities also include Dynamic Treatment Plan, which lets clinicians set personalized medication adjustment plans based on pressure changes. Once configured, the feature can send medication instructions directly to patients through the app. Abbott plans to make the app and Dynamic Treatment Plan available later in 2026.
Abbott (ABT) will announce its third-quarter 2026 financial results on October 21, before the market opens, followed by an earnings call. The live webcast starts at 8 a.m. Central time (9 a.m. Eastern) on Abbott's Investor Relations website, www.abbottinvestor.com. An archived edition will be available later that day.